Abbott (NYSE: ABT) announced positive one-year clinical results from the ABSORB III trial, which compared the safety and effectiveness of ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE